Chemical Abstracts Service (CAS), the world's authority for chemical information, has announced a landmark five-year agreement for SciFinder, the choice for chemistry research, with AstraZeneca, a biopharmaceutical company specialising in the discovery, development, manufacturing and marketing of prescription medicines. The long-term agreement guarantees AstraZeneca researchers access to the most accurate, comprehensive and current research, available only in SciFinder.
An early adopter of Enterprise-Wide Pricing, AstraZeneca has relied on SciFinder to meet the needs of its researchers for nearly a decade, and this five-year agreement is a first for SciFinder within the pharmaceutical industry. It signifies the confidence customers have in CAS as a high-quality information partner providing reliable access to the most up-to-date research in the chemical industry and beyond, according to the company.
A division of the American Chemical Society, CAS claims to be the only organisation in the world whose objective is to find, collect and organise all publicly disclosed substance information. A team of scientists worldwide curates and controls the quality of the databases, which are recognised as the most comprehensive and authoritative by chemical and pharmaceutical companies, universities, government organizations and patent offices around the world. By combining these databases with advanced search and analysis technologies (SciFinder® and STN®), CAS delivers the most current, complete, secure and interlinked digital information environment for scientific discovery.
